Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors von Cristescu, Razvan, Aurora-Garg, Deepti, Albright, Andrew, Xu, Lei, Liu, Xiao Qiao, Loboda, Andrey, Lang, Lixin, Jin, Fan, Rubin, Eric H, Snyder, Alexandra, Lunceford, Jared

Volltext

Rendering the 3 + 3 Design to Rest: More Efficient Approaches to Oncology Dose-Finding Trials in the Era of Targeted Therapy von Nie, Lei, Rubin, Eric H, Mehrotra, Nitin, Pinheiro, José, Fernandes, Laura L, Roy, Amit, Bailey, Stuart, de Alwis, Dinesh P

Volltext

Antitumor activity in RAS-driven tumors by blocking AKT and MEK von Tolcher, Anthony W, Khan, Khurum, Ong, Michael, Banerji, Udai, Papadimitrakopoulou, Vassiliki, Gandara, David R, Patnaik, Amita, Baird, Richard D, Olmos, David, Garrett, Christopher R, Skolnik, Jeffrey M, Rubin, Eric H, Smith, Paul D, Huang, Pearl, Learoyd, Maria, Shannon, Keith A, Morosky, Anne, Tetteh, Ernestina, Jou, Ying-Ming, Papadopoulos, Kyriakos P, Moreno, Victor, Kaiser, Brianne, Yap, Timothy A, Yan, Li, de Bono, Johann S

Volltext

Epothilones: Mechanism of Action and Biologic Activity von GOODIN, Susan, KANE, Michael P, RUBIN, Eric H

Volltext

Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors von Tan, Antoinette R, Rubin, Eric H, Walton, Diana C, Shuster, Dale E, Wong, Y Nancy, Fang, Fang, Ashworth, Simon, Rosen, Lee S

Volltext

From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely von Day, Daphne, Monjazeb, Arta M, Sharon, Elad, Ivy, S Percy, Rubin, Eric H, Rosner, Gary L, Butler, Marcus O

Volltext

Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors:... von HERBST, Roy S, MADDOX, Anne-Marie, OCHS, Judith, MUCCI LORUSSO, Patricia, ROTHENBERG, Mace L, SMALL, Eric J, RUBIN, Eric H, BASELGA, Jose, ROJO, Federico, WAUN KI HONG, SWAISLAND, Helen, AVERBUCH, Steven D

Volltext

Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor von Iwamoto, Marian, Friedman, Evan J., Sandhu, Punam, Agrawal, Nancy G. B., Rubin, Eric H., Wagner, John A.

Volltext

Mechanisms of resistance to topoisomerase I-targeting drugs von Rasheed, Zeshaan A, Rubin, Eric H

Volltext

Adaptive phase 2/3 designs for oncology drug development – Time to hedge von Chen, Cong, Rubin, Eric H.

Volltext

Topors Functions as an E3 Ubiquitin Ligase with Specific E2 Enzymes and Ubiquitinates p53 von Rajendra, Rajeev, Malegaonkar, Diptee, Pungaliya, Pooja, Marshall, Henderson, Rasheed, Zeshaan, Brownell, James, Liu, Leroy F, Lutzker, Stuart, Saleem, Ahamed, Rubin, Eric H

Volltext

Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Neutropenia during Phase I Development of Liposome-Entrapped Paclitaxel von FETTERLY, Gerald J, GRASELA, Thaddeus H, RUBIN, Eric H, TAN, Antoinette R, SHERMAN, Jeffrey W, DUL, Jeanne L, GRAHN, Amy, LECOMTE, Diane, FIEDLER-KELLY, Jill, DAMJANOV, Nevena, FISHMAN, Mayer, KANE, Michael P

Volltext

Pharmacokinetics of Cetuximab After Administration of Escalating Single Dosing and Weekly Fixed Dosing in Patients with Solid Tumors von TAN, Antoinette R, MOORE, Dirk F, HIDALGO, Manuel, DOROSHOW, James H, POPLIN, Elizabeth A, GOODIN, Susan, MAURO, David, RUBIN, Eric H

Volltext

A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53 -mutant Ovarian Cancer von Oza, Amit M, Estevez-Diz, Maria, Grischke, Eva-Maria, Hall, Marcia, Marmé, Frederik, Provencher, Diane, Uyar, Denise, Weberpals, Johanne I, Wenham, Robert M, Laing, Naomi, Tracy, Michael, Freshwater, Tomoko, Lee, Mark A, Liu, Ji, Qiu, Jingjun, Rose, Shelonitda, Rubin, Eric H, Moore, Kathleen

Volltext

Phase I Dose-Finding Study of Weekly Single-Agent Patupilone in Patients With Advanced Solid Tumors von RUBIN, Eric H, ROTHERMEL, John, TESFAYE, Fisseha, TIANLING CHEN, HUBERT, Martine, HO, Yu-Yun, HSU, Chyi-Hung, OZA, Amit M

Volltext

A Study to Determine the Effects of Food and Multiple Dosing on the Pharmacokinetics of Vorinostat Given Orally to Patients with Advanced Cancer von RUBIN, Eric H, AGRAWAL, Nancy G. B, WAGNER, John A, IWAMOTO, Marian, FRIEDMAN, Evan J, SCOTT, Pamela, MAZINA, Kathryn E, SUN, Linda, LIHONG DU, RICKER, Justin L, FRANKEL, Stanley R, GOTTESDIENER, Keith M

Volltext

A Single Supratherapeutic Dose of Vorinostat Does Not Prolong the QTc Interval in Patients with Advanced Cancer von Munster, Pamela N, Rubin, Eric H, Van Belle, Simon, Friedman, Evan, Patterson, Jaclyn K, Van Dyck, Kristien, Li, Xiadong, Comisar, Wendy, Chodakewitz, Jeffery A, Wagner, John A, Iwamoto, Marian

Volltext

The BATTLE trial: a bold step toward improving the efficiency of biomarker-based drug development von Rubin, Eric H, Anderson, Keaven M, Gause, Christine K

Volltext

Challenges with Novel Clinical Trial Designs: Master Protocols von Cecchini, Michael, Rubin, Eric H, Blumenthal, Gideon M, Ayalew, Kassa, Burris, Howard A, Russell-Einhorn, Michele, Dillon, Hildy, Lyerly, H Kim, Reaman, Gregory H, Boerner, Scott, LoRusso, Patricia M

Volltext

Transcription-Dependent Degradation of Topoisomerase I-DNA Covalent Complexes von Desai, Shyamal D., Zhang, Hui, Rodriguez-Bauman, Alexandra, Yang, Jin-Ming, Wu, Xiaohua, Gounder, Murugesan K., Rubin, Eric H., Liu, Leroy F.

Volltext